Latest Financial Health News

Metallium Ltd has completed a A$50 million institutional raise, secured a Texas site, and validated its commercial Flash Joule Heating reactor, setting the stage for its first U.S. metals recovery plant commissioning by year-end 2025.

RLF AgTech reports a robust 74% increase in customer cash receipts for FY2025, alongside a significant expansion of its Australian distribution network and strong pre-orders from China, signaling a promising start to FY2026.

Triton Minerals updates investors on ongoing legal disputes over its Mozambique graphite project SSAP, rejecting a recent counterproposal and enacting strict cost-cutting measures to preserve cash.

Finbar Group has reinstated regular dividends with a fully franked 2 cent final payout for FY25, supported by a robust $36 million cash reserve and a strong development pipeline exceeding $1 billion in value.

Pengana Capital Group has reported a solid increase in funds under management, reaching $3.64 billion as of June 30, 2025, alongside modest net performance fees and upcoming distributions.

Ava Risk Group has suspended its dividend policy to reinvest capital into its growth strategy, signaling a shift in priorities for shareholders. The board will reassess this stance annually.

Advanced Health Intelligence has been formally delisted from NASDAQ due to shareholder equity deficiencies but is actively pursuing ASX reinstatement as a critical step toward regaining its dual-listing status.

Great Dirt Resources has secured a significant exploration licence in the Pilbara lithium province and bolstered its finances with a $335,000 R&D tax rebate, setting the stage for accelerated exploration activities.

Kingsgate Consolidated’s Chatree Gold Mine delivered a robust quarter with gold production exceeding 20,000 ounces, aligning with its revised FY25 guidance and boosting cash reserves.

Archer Materials advances its quantum computing and medical diagnostics technologies, extending key partnerships and forming a new advisory board while maintaining a strong cash position to fuel development.

Pharmx Technologies has resumed trading on the ASX following the renewal of its pivotal National Diabetes Services Scheme agreement, signaling stability for the healthcare tech firm.

Mach7 Technologies maintains its FY25 revenue growth guidance with strong recurring revenue gains, despite a modest shortfall in contracted annual recurring revenue. The company also advances its share buyback program, signaling confidence in its financial position.